These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [Is there an indication for adjuvant or neoadjuvant systemic therapy in prostate cancer?]. Börgermann C; Miller K; vom Dorp F; Jäger T; Rübben H Urologe A; 2007 Oct; 46(10):1385-6, 1388. PubMed ID: 17874231 [TBL] [Abstract][Full Text] [Related]
29. New agents in the therapy of hormone-refractory patients with prostate cancer. Kantoff PW Semin Oncol; 1995 Feb; 22(1 Suppl 1):32-4. PubMed ID: 7532323 [No Abstract] [Full Text] [Related]
30. Prostate cancer: an evolving paradigm. Caso JR; Mouraviev V; Tsivian M; Polascik TJ; Moul JW J Endourol; 2010 May; 24(5):805-9. PubMed ID: 20367442 [TBL] [Abstract][Full Text] [Related]
31. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850 [TBL] [Abstract][Full Text] [Related]
32. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate]. Culine S Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025 [No Abstract] [Full Text] [Related]
33. [Updates on molecular markers of prostatic cancer]. Chang B; Li F; Song LJ Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):339-41. PubMed ID: 18956656 [No Abstract] [Full Text] [Related]
34. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Denmeade SR; Isaacs JT Cancer J Sci Am; 1998 May; 4 Suppl 1():S15-21. PubMed ID: 9619266 [No Abstract] [Full Text] [Related]
35. Chemotherapy in the treatment of prostate cancer--is there a role? Arianayagam M; Chang J; Rashid P Aust Fam Physician; 2007 Sep; 36(9):737-9. PubMed ID: 17885709 [TBL] [Abstract][Full Text] [Related]
36. Inflammatory pathogenesis of prostate cancer and celecoxib. Mathew P J Clin Oncol; 2010 Apr; 28(12):e197; author reply e198. PubMed ID: 20177014 [No Abstract] [Full Text] [Related]
38. Molecular and traditional chemotherapy: a united front against prostate cancer. Singh P; Yam M; Russell PJ; Khatri A Cancer Lett; 2010 Jul; 293(1):1-14. PubMed ID: 20117879 [TBL] [Abstract][Full Text] [Related]
39. Adjuvant and neoadjuvant therapies in high risk localized prostate cancer. Giannakopoulos X; Stagikas D; Charalabopoulos A; Sofikitis N; Charalabopoulos K J Exp Clin Cancer Res; 2006 Dec; 25(4):469-73. PubMed ID: 17310835 [TBL] [Abstract][Full Text] [Related]
40. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy. Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]